M. David Percival - Concepedia

Author

M. David Percival

Also Known As

M D Percival, M David Percival, M. D. PERCIVAL, M. D. Percival, M. David PERCIVAL, M. David Percival, M. Percival, M.D Percival, M.D. Percival, M.David Percival

Publications

6.1K

Citations

H-Index

Concepts

All Affiliations

Merck Canada Inc. (Canada)Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy TransCanada (Canada)University of British Columbia

About

M. David Percival is an author at Merck Canada Inc. (Canada) specializing in medicine, biochemistry, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	46	3.9K
2	Natural Sciences	25	29	2.7K
3	Engineering	3	3	114
4	Health Sciences	1	1	18
5	Allergy	1	1	47

M. David Percival

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K Jacques Yves Gauthier, Nathalie Chauret, Wanda Cromlish, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyPharmaceutical ChemistryBiochemistryMedicineNatural Sciences	2008	467
Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2 Denis Riendeau, M. David Percival, Christine Brideau, Journal of Pharmacology and Experimental Therapeutics	2001	456
The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor Petpiboon Prasit, Z Wang, Christine Brideau, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryActive Cyclooxygenase-2 InhibitorPharmaceutical ScienceBiochemistry	1999	426
Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles Chi‐Chung Chan, S. Boyce, Christine Brideau, Journal of Pharmacology and Experimental Therapeutics	1999	397
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor Denis Riendeau, M. David Percival, S. Boyce, British Journal of Pharmacology Pge2 ProductionChemoprevention StrategyImmunologyPharmacotherapyPharmaceutical Chemistry	1997	326
Mechanism of Acetaminophen Inhibition of Cyclooxygenase Isoforms Marc Ouellet, M. David Percival Archives of Biochemistry and Biophysics BiochemistryMedicineExperimental PharmacologyPharmacotherapyAcetaminophen Inhibition	2001	167
Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms Marc Ouellet, M. David Percival Biochemical Journal PharmacotherapyInflammationMedicinal ChemistryKey EnzymeAnti-cancer Agent	1995	157
Lysosomotropism of Basic Cathepsin K Inhibitors Contributes to Increased Cellular Potencies against Off-Target Cathepsins and Reduced Functional Selectivity Jean‐Pierre Falgueyret, Sylvie Desmarais, Renata M. Oballa, Journal of Medicinal Chemistry	2005	152
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin Marc Ouellet, Denis Riendeau, M. David Percival Proceedings of the National Academy of Sciences	2001	139
Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K W. Cameron Black, Christopher I. Bayly, Dana Davis, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryDerivative (Chemistry)BiochemistryNatural SciencesMedicine	2005	137

Page 1